Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Pro Medicus Limited ( (AU:PME) ).
Pro Medicus Limited has announced the quotation of 47,930 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of August 25, 2025. This move reflects the company’s ongoing efforts to enhance its market presence and provide value to its stakeholders by expanding its financial instruments available for trading.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$361.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
More about Pro Medicus Limited
Pro Medicus Limited operates in the healthcare technology industry, providing advanced imaging and information technology solutions. The company focuses on delivering innovative software and services for medical imaging and healthcare systems, catering to a global market.
YTD Price Performance: 22.62%
Average Trading Volume: 175,830
Technical Sentiment Signal: Buy
Current Market Cap: A$32.01B
For a thorough assessment of PME stock, go to TipRanks’ Stock Analysis page.